3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers

Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock.

Zacks Investment Research • Jan 27, 2026

5 ETFs to Buy for January

5 ETFs to buy in January: momentum, small caps, chips, defense and healthcare shine as markets rally early in 2026 -- IWM, MTUM, SMH, XAR and IHE.

Zacks Investment Research • Jan 8, 2026

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the iShares U.S. Pharmaceuticals ETF (IHE), a passively managed exchange traded fund launched on May 1, 2006.

Zacks Investment Research • Jan 7, 2026

Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends

XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.

Zacks Investment Research • Dec 22, 2025

Pharma's $370B Bet on America: The ETF Plays for 2026

Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.

Zacks Investment Research • Dec 19, 2025

Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts

As big pharmaceutical companies are set to finalize a deal with the U.S. government to bring down prices for some prescription drugs, another old question is coming into focus for investors: how much damage can Washington really do to Big Pharma's bottom line?

Benzinga • Dec 19, 2025

3 Dividend ETFs to Buy and Hold for Life if the Market Crashes

Dividend ETFs may be the best investment you can make today.

24/7 Wall Street • Dec 11, 2025

Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal

Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.

Zacks Investment Research • Dec 9, 2025

IHE: Pharma Powerhouse ETF Despite High Fees And Valuation

iShares U.S. Pharmaceuticals ETF is rated a buy, driven by strong growth and dividends from top holdings like Eli Lilly, JNJ, and Merck. IHE's top holdings, particularly LLY, JNJ, and MRK, offer diverse product lines, robust earnings, and expanding dividends, supporting future performance. Despite IHE's high expense ratio and sector concentration, the growth and profitability of its largest components outweigh these drawbacks.

Seeking Alpha • Nov 27, 2025

Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Zacks Investment Research • Nov 14, 2025